Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 12:14:870517.
doi: 10.3389/fnagi.2022.870517. eCollection 2022.

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab

Mingchao Shi  1 , Fengna Chu  1 , Feiqi Zhu  2 , Jie Zhu  1   3
Affiliations
Review

Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab

Mingchao Shi et al. Front Aging Neurosci. .

Abstract

Alzheimer's disease (AD) is the most prevalent form of age-related dementia in the world, and its main pathological features consist of amyloid-β (Aβ) plaque deposits and neurofibrillary tangles formed by hyperphosphorylated tau protein. So far, only a few AD treatments approved have been applied in the clinic, but the effects of these drugs are limited only for partial symptomatic relief to patients with AD and are unable to alter AD progression. Later, all efforts for AD treatments with targeting the pathogenic factors were unsuccessful over the past decades, which suggested that the pathogenesis of AD is complex. Recently, disease-modifying therapies (DMTs) that can change the underlying pathophysiology of AD, with anti-Aβ monoclonal antibodies (mabs) (e.g., aducanumab, bapineuzumab, gantenerumab, solanezumab, and lecanemab) have been developed successively and conducted in clinical trials based on the theory that a systemic failure of cell-mediated Aβ clearance contributes to AD occurrence and progression. In the review, we summarized recent studies on the therapeutic effects and clinical trial results of these mabs in patients with AD. Specifically, we focused on the discussion of the impact of aducanumab and lecanemab on AD pathology and clinical profiles. The review provides a possible evidence for applying immunotherapy with anti-Aβ mabs in AD and analyzes lessons learned from these clinical trials in order to further study the therapeutic and adverse effects of these anti-Aβ mabs on AD.

Keywords: Alzheimer’s disease; aducanumab; amyloid-β; lecanemab; monoclonal antibodies; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abushakra S., Porsteinsson A., Scheltens P., Sadowsky C., Vellas B., Cummings J., et al. (2017). Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild alzheimer’s disease suggest disease modification potential. J. Prev. Alzheimers Dis. 4 149–156. 10.14283/jpad.2017.26 - DOI - PubMed
    1. Abushakra S., Porsteinsson A., Vellas B., Cummings J., Gauthier S., Hey J. A., et al. (2016). Clinical benefits of tramiprosate in alzheimer’s disease are associated with higher number of APOE4 alleles: the “APOE4 gene-dose effect”. J. Prev. Alzheimers Dis. 3 219–228. 10.14283/jpad.2016.115 - DOI - PubMed
    1. Alexiou A., Chatzichronis S., Ashraf G. M. (2020). “Prediction of Alzheimer’s disease,” in Diagnosis and Management in Dementia, eds Martin C. R., Preedy V. R. (Boston: Academic Press; ), 365–378.
    1. Angelucci F., Cechova K., Amlerova J., Hort J. (2019). Antibiotics, gut microbiota, and Alzheimer’s disease. J. Neuroinflammation 16:108. 10.1186/s12974-019-1494-4 - DOI - PMC - PubMed
    1. Arndt J. W., Qian F., Smith B. A., Quan C., Kilambi K. P., Bush M. W., et al. (2018). Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci. Rep. 8:6412. 10.1038/s41598-018-24501-0 - DOI - PMC - PubMed